We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Increases Yet Falls Behind Market: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Cardinal Health (CAH - Free Report) was up +2.42% at $211.31. The stock fell short of the S&P 500, which registered a gain of 2.91% for the day. Meanwhile, the Dow gained 2.49%, and the Nasdaq, a tech-heavy index, added 3.83%.
The prescription drug distributor's shares have seen a decrease of 10.25% over the last month, not keeping up with the Medical sector's loss of 9.63% and the S&P 500's loss of 7.64%.
The investment community will be paying close attention to the earnings performance of Cardinal Health in its upcoming release. The company is slated to reveal its earnings on April 30, 2026. The company is predicted to post an EPS of $2.8, indicating a 19.15% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $62.42 billion, indicating a 13.74% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $10.31 per share and revenue of $259.27 billion. These totals would mark changes of +25.12% and +16.48%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Cardinal Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Cardinal Health is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, Cardinal Health currently has a Forward P/E ratio of 20. This represents a premium compared to its industry average Forward P/E of 15.01.
Investors should also note that CAH has a PEG ratio of 1.33 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CAH's industry had an average PEG ratio of 1.77 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 52, positioning it in the top 22% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Cardinal Health (CAH) Increases Yet Falls Behind Market: What Investors Need to Know
In the latest close session, Cardinal Health (CAH - Free Report) was up +2.42% at $211.31. The stock fell short of the S&P 500, which registered a gain of 2.91% for the day. Meanwhile, the Dow gained 2.49%, and the Nasdaq, a tech-heavy index, added 3.83%.
The prescription drug distributor's shares have seen a decrease of 10.25% over the last month, not keeping up with the Medical sector's loss of 9.63% and the S&P 500's loss of 7.64%.
The investment community will be paying close attention to the earnings performance of Cardinal Health in its upcoming release. The company is slated to reveal its earnings on April 30, 2026. The company is predicted to post an EPS of $2.8, indicating a 19.15% growth compared to the equivalent quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $62.42 billion, indicating a 13.74% growth compared to the corresponding quarter of the prior year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $10.31 per share and revenue of $259.27 billion. These totals would mark changes of +25.12% and +16.48%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Cardinal Health. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Cardinal Health is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, Cardinal Health currently has a Forward P/E ratio of 20. This represents a premium compared to its industry average Forward P/E of 15.01.
Investors should also note that CAH has a PEG ratio of 1.33 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CAH's industry had an average PEG ratio of 1.77 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 52, positioning it in the top 22% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.